SCHEMBL16669141

SCHEMBL16669141

CC(CCCCC(=O)O)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.39
FFAR1 O14842 2/20 0.39
ALDH1A1 P00352 4/20 0.38
GSTK1 Q9Y2Q3 2/20 0.37
LMNA P02545 2/20 0.37
ENPEP Q07075 1/20 0.36
TSHR P16473 4/20 0.35
NFKB1 P19838 1/20 0.35
PMP22 Q01453 1/20 0.35
AKR1B1 P15121 1/20 0.35
PPARG P37231 4/20 0.34
PPARD Q03181 4/20 0.34
PPARA Q07869 4/20 0.34
GPR84 Q9NQS5 3/20 0.34
HDAC11 Q96DB2 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
SLC22A6 Q4U2R8 1/20 0.34
SLC22A8 Q8TCC7 1/20 0.34
TLR2 O60603 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939304 0.95 FOLH1 (0.35) FFAR4FFAR1ALDH1A1GSTK1LMNA
SCHEMBL4943234 0.95 FOLH1 (0.35) FFAR4FFAR1ALDH1A1GSTK1LMNA
SCHEMBL4317387 0.88 GABRP (0.41) ENPEPTSHRNFKB1MEN1KMT2A
SCHEMBL4317383 0.88 GABRP (0.41) ENPEPTSHRNFKB1MEN1KMT2A
SCHEMBL13619245 0.84 CA2 (0.31)
SCHEMBL517865 0.83 FFAR4 (0.42) FFAR4FFAR1ALDH1A1GSTK1LMNA
SCHEMBL16145709 0.83 GPR84 (0.47) FFAR4FFAR1LMNAGPR84SLC22A6
SCHEMBL16682592 0.82
SCHEMBL9117153 0.81 CA2 (0.31) ALDH1A1
SCHEMBL16928574 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118922409-A Asymmetric piperazine-based cationic lipids 翻译生物公司 2024-11-08 CN disclosed
US-9315486-B2 Therapeutic cyclopentanols, compositions thereof, and methods for use thereof ALLERGAN, INC. (US) 2016-04-19 US disclosed
US-20150119454-A1 THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF ALLERGAN, INC. 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119454-A1 THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF PTGIS, PDE3A, PTGIR FFAR4 2296/4885FFAR1 2084/4885ALDH1A1 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.